Intravitreal administration

Results: 30



#Item
21NDA[removed]S-018 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use MACUGEN® safely and effectively. See full

NDA[removed]S-018 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use MACUGEN® safely and effectively. See full

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-10-20 14:37:56
22The committee will discuss saxagliptin tablets, by Bristol-Myers Squibb, for the treatment of hyperglycemia in adults with type 2 diabetes mellitus

The committee will discuss saxagliptin tablets, by Bristol-Myers Squibb, for the treatment of hyperglycemia in adults with type 2 diabetes mellitus

Add to Reading List

Source URL: www.fda.gov

Language: English
23March 6, 2006 Dear Health Care Professional, (OSI) Eyetech Inc. and Pfizer Inc. would like to inform you about important changes in the Macugen® (pegaptanib sodium injection) Prescribing Information concerning reports o

March 6, 2006 Dear Health Care Professional, (OSI) Eyetech Inc. and Pfizer Inc. would like to inform you about important changes in the Macugen® (pegaptanib sodium injection) Prescribing Information concerning reports o

Add to Reading List

Source URL: www.fda.gov

Language: English
24NDA[removed]S-007 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZURDEX® safely and effectively. See full prescribing information

NDA[removed]S-007 Page 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZURDEX® safely and effectively. See full prescribing information

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-09-11 15:54:35
25BLA[removed]Page 4 ________ WARNINGS AND PRECAUTIONS _________ •		 Decreases in vision due to progression of the condition with traction may occur requiring

BLA[removed]Page 4 ________ WARNINGS AND PRECAUTIONS _________ • Decreases in vision due to progression of the condition with traction may occur requiring

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-06-17 15:06:54
26HIGHLIGHTS OF PRESCRIBING INFORMATION  DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA.

HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA.

Add to Reading List

Source URL: www.regeneron.com

Language: English - Date: 2014-02-14 16:41:40
27OZURDEX® Prescribing Information

OZURDEX® Prescribing Information

Add to Reading List

Source URL: www.allergan.com

Language: English - Date: 2014-02-10 19:31:08
28Intraviteal injections.pub

Intraviteal injections.pub

Add to Reading List

Source URL: www.retina-assoc.com

Language: English - Date: 2011-09-24 20:43:02
29Intraviteal injections.pub

Intraviteal injections.pub

Add to Reading List

Source URL: www.retina-doctors.com

Language: English - Date: 2011-09-24 20:43:02
30Macugen EPAR Summary update for II-47

Macugen EPAR Summary update for II-47

Add to Reading List

Source URL: www.ema.europa.eu

Language: English - Date: 2013-07-21 05:13:11